BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Monte Rosa Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
2025-05-15 4:33 pm Purchase |
2025-03-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
BIOTECHNOLOGY VALUE FUND L P | 5,660,132 9.200% |
1,266,922![]() (+28.84%) |
Filing |
2025-01-31 6:43 pm Purchase |
2025-01-24 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
BIOTECHNOLOGY VALUE FUND L P | 4,393,210 7.200% |
4,393,210![]() (New Position) |
Filing |